Head-to-head evidence
Aflibercept vs Ranibizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
Aflibercept · Eylea
Marketed by Regeneron Pharmaceuticals and partners
NCT00509795 · Phase 3 · completed
The trial randomly assigned 1,217 participants and used quadruple blinding with ranibizumab as an active comparator. Its hard clinical primary endpoint—maintaining vision at week 52—met the prespecified non-inferiority criterion for all three aflibercept regimens, supporting a strong evidence grade.
Next expected readout: December 2026 · NCT06856577 (registry estimate)
Ranibizumab · Lucentis
Marketed by Roche and partners
NCT00056836 · Phase 3 · completed
The study was randomized and double-masked and enrolled 720 participants, but the registry does not identify the comparator arm or provide results. Because the primary clinical endpoint and whether it was met cannot be verified, the evidence remains limited despite the substantial trial size and controlled design.
Next expected readout: February 2027 · NCT04657289 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aflibercept's landscape · Ranibizumab's landscape